The subsequent ARC-10 trial, which was presented in November 2024 during a poster session at the Society for Immunotherapy of Cancer (SITC) annual meeting, demonstrated improved overall survival (OS) for the combination of domvanalimab with zimberelimab in patients with high PD-L1 expression of non-small cell lung cancer. This evidence concerns the gene CD274 and non-small cell lung carcinoma.